(Q40509781)

21 September 2017

title

Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin (English)

1 reference

21 September 2017

Efstathios Kastritis

5

0 references

Athanasios Dimopoulos

object named as

Meletios A Dimopoulos

8

0 references

Aristotle Bamias

2

object named as

Aristotle Bamias

1 reference

21 September 2017

3

Eleni Efstathiou

1 reference

21 September 2017

Georgios Chamilos

1

1 reference

21 September 2017

Pagona M Zorzou

4

1 reference

21 September 2017

Evagelos Kostis

6

1 reference

21 September 2017

Christos Papadimitriou

7

1 reference

21 September 2017

language of work or name

English

0 references

publication date

1 June 2005

1 reference

21 September 2017

1 reference

21 September 2017

volume

103

1 reference

21 September 2017

issue

12

1 reference

21 September 2017

page(s)

2629-2635

1 reference

Quantitative Relationships Between Circulating Leukocytes and Infection in Patients with Acute Leukemia

21 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21089

Septicemia and Shock Syndrome Due to Viridans Streptococci: A Case-Control Study of Predisposing Factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21089

2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21089

7 January 2021

Controversies in the management of febrile neutropenic cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21089

7 January 2021

Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21089

7 January 2021

The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21089

7 January 2021

Oral versus Intravenous Empirical Antimicrobial Therapy for Fever in Patients with Granulocytopenia Who Are Receiving Cancer Chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21089

7 January 2021

A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21089

7 January 2021

Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21089

7 January 2021

Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21089

7 January 2021

Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: results of a prospective randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21089

7 January 2021

Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21089

7 January 2021

Fever and neutropenia--how to use a new treatment strategy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21089

7 January 2021

Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21089

7 January 2021

Management of the febrile neutropenic patient: a consensus conference

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21089

7 January 2021

https://api.crossref.org/works/10.1002%2FCNCR.21089

1 reference

7 January 2021

Moxifloxacin activity against clinical isolates compared with the activity of ciprofloxacin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21089

7 January 2021

In vitro antimicrobial activity of moxifloxacin compared to other quinolones against recent clinical bacterial isolates from hospitalized and community-based cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21089

7 January 2021

Outpatient treatment of neutropenic fever with oral antibiotics and granulocyte colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21089

7 January 2021

Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21089

7 January 2021

Management of fever in neutropenic patients with different risks of complications

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21089

7 January 2021

Antimicrobial therapy of unexplained fever in neutropenic patients--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeits

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21089

7 January 2021

Comparative activity of new quinolones against 326 clinical isolates of Stenotrophomonas maltophilia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21089

7 January 2021

Activity of moxifloxacin against pathogens with decreased susceptibility to ciprofloxacin.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21089

7 January 2021

Identifiers

DOI

10.1002/CNCR.21089

1 reference

21 September 2017

1 reference